Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder
University Hospitals Cleveland Medical Center · NCT03829787
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- March 27, 2019
- Record last updated
- October 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to use eye-tracking technology to study attentional biases, reward sensitivity, and cognitive control in adult patients with bipolar disorder with or without anxiety and/or substance use disorder comorbidity.
Being studied: Eye tracking
Conditions: Bipolar Disorder
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
- Inclusion and Exclusion Criteria for Group 1: bipolar disorder without current anxiety or substance use disorder
- Inclusion Criteria for Group 1:
i. Male or female, age 18 or older
ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to Diagnostic and Statistical Manual-5 (DSM-5) criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
iii. Currently in a depressive episode or currently in remission from a mood episode
iv. Young Mania Rating Scale total score ≤ 8
v. In the opinion of the investigator, capable of understanding and complying with protocol requirements
vi. In the opinion of the investigator, has the competency to understand and sign the informed consent
vii. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
b. Exclusion Criteria for Group 1:
i. Significant structural brain lesion (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any current psychiatric disorder (other than a current depressive episode) including anxiety disorders, substance use disorders, antisocial personality disorder and borderline personality disorder as assessed by the MINI and clinician assessment.
iv. Currently pregnant or planning to become pregnant
v. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
vi. Currently taking any steroids, stimulants, or opioid pain killers.
vii. Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine.Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
viii. Has had electroconvulsive therapy (ECT) treatment within the last 6 months.
- Inclusion and Exclusion Criteria for Group 2: Bipolar disorder with a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia)
a. Inclusion Criteria for Group 2:
i. Male or female, age 18 or older
ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
iii. Currently in a depressive episode or currently in remission from a mood episode
iv. Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI)
v. Hamilton Anxiety Rating Scale total score ≥ 18
vi. Young Mania Rating Scale total score ≤ 8
vii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
viii. In the opinion of the investigator, has the competency to understand and sign the informed consent
ix. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
b. Exclusion Criteria for Group 2:
i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD)
iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
v. Currently pregnant or planning to become pregnant
vi. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
vii. Currently taking any steroids, stimulants, or opioid pain killers.
viii. Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine
ix. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
x. Has had ECT treatment within the last 6 months.
- Inclusion and Exclusion Criteria for Group 3: Bipolar disorder with a current anxiety disorder and a current substance use disorder
a. Inclusion Criteria for Group 3:
i. Male or female, age 18 or older
ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
iii. Meets diagnostic criteria for a substance use disorder within the last 3 months
iv. Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI)
v. Currently in a depressive episode or currently in remission from a mood episode
vi. Hamilton Anxiety Rating Scale total score ≥ 18
vii. Young Mania Rating Scale total score ≤ 8
viii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
ix. In the opinion of the investigator, has the competency to understand and sign the informed consent
x. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
b. Exclusion Criteria for Group 3:
i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD)
iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
v. Intoxicated or in acute withdrawal state.
vi. Currently pregnant or planning to become pregnant.
vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
viii. Has had ECT treatment within the last 6 months.
- Inclusion and Exclusion Criteria for Group 4: Bipolar disorder without an anxiety disorder but with a current substance use disorder
a. Inclusion Criteria for Group 4:
i. Male or female, age 18 or older
ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
iii. Meets diagnostic criteria for a substance use disorder within the last 3 months
iv. Currently in a depressive episode or currently in remission from a mood episode
v. Young Mania Rating Scale total score ≤ 8
vi. Hamilton Anxiety Rating Scale total score ≤ 12
vii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
viii. In the opinion of the investigator, has the competency to understand and sign the informed consent
ix. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
b. Exclusion Criteria for Group 4:
i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any co-occurring current anxiety disorder or attention deficit hyperactivity disorder (ADHD)
iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
v. Intoxicated or in an acute withdrawal state
vi. Currently pregnant or planning to become pregnant.
vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
viii. Has had ECT treatment within the last 6 months.
- Inclusion and exclusion criteria for Group 5: Healthy Volunteers
- Inclusion criteria for Group 5:
i. Male or female, age 18 or older
ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
iii. In the opinion of the investigator, has the competency to understand and sign the informed consent
iv. Physically healthy as determined by research psychiatrist
v. Without any current and/or lifetime psychiatric disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI)
b. Exclusion Criteria for Group 5:
i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any psychiatric disorder including any severe personality disorder
iv. Currently pregnant or planning to become pregnant
v. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
vi. Currently taking any steroids, stimulants, or opioid pain killers.
vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
Recruiting US locations
University Hospitals Cleveland Medical Center - Mood Disorders Program
Cleveland, OH 44106
Site contact: Nicole Jones, MA · 216-844-2862 · mdp@UHhospitals.org
Study contacts (from the official record)
- Nicole Jones · 216/844-2862 · mdp@uhhospitals.org
Similar studies in Ohio
All mental health studies in Ohio →- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Cincinnati, OH + 50 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Bristol-Myers Squibb
- Location
- North Canton, OH + 18 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With…
LivaNova
- Location
- Columbus, OH + 49 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bristol-Myers Squibb
- Location
- Cincinnati, OH + 20 other US sites
- Eligibility basics
- Ages 18–65